Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDIV 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 2Papillomavirus Infections 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Inflammatory Bowel Diseases 1Infertility 1High Grade Cervical Intraepithelial Neoplasia 1

Interventions

Infliximab 3Tea 2Polyethylene Glycols 2Lidocaine 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2sodium phosphate 1purine 1prucalopride 1picosulfate sodium 1golimumab 1fumaric acid 1Sulfasalazine 1Pneumococcal Vaccines 1Passive Cutaneous Anaphylaxis 1Papillomavirus Vaccines 1Narrow Band Imaging 1Morphine 1Methotrexate 1Mesalamine 1Mercaptopurine 1MEDI2070 1Exercise 1Etanercept 1Dietary Supplements 1Diatrizoate Meglumine 1Diagnostic Imaging 1Calcium Dobesilate 1CT-P13 1Bupivacaine 1Bisacodyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Inflammatory Bowel Diseases × Biological Products × Clear all
NCT01974869 2017-02-07

Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response

El-Hussuna, Alaa, M.D.

Completed
47 enrolled

Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡